10-Q: Splash Beverage Group Q1 2026: Strategic Shift & Medterra Deal

Splash Beverage Group reports a significant strategic pivot towards the cannabinoid market with a proposed Medterra acquisition, alongside a substantial decrease in beverage revenue and ongoing liquidity concerns.

Summary

• Splash Beverage Group's Q1 2026 results show a drastic decline in beverage revenue, with a focus shifting to the regulated wellness and cannabinoid markets.
• The company is pursuing a potential business combination with Medterra CBD, LLC, a manufacturer of cannabinoid wellness products.
• This proposed acquisition involves an enterprise value of $37.6 million for Medterra and requires Splash to raise approximately $10 million to pay off Medterra's debt and cover taxes.
• The company continues to face significant liquidity challenges, with current liabilities exceeding current assets and a substantial accumulated deficit.
• Splash is also under scrutiny by the NYSE American for failing to meet continued listing standards regarding shareholder equity and is at risk of delisting.
• Management is actively exploring alternative transactions in the wellness and cannabinoid sectors due to the evolving market and the uncertainty surrounding the Medterra deal.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to severe revenue decline, significant liquidity issues, ongoing risk of delisting, and the uncertainty surrounding the proposed acquisition, despite strategic efforts to pivot.

Positives

• The company is actively pursuing a strategic shift into the growing regulated wellness and cannabinoid markets.
• A non-binding letter of intent has been signed for a potential acquisition of Medterra CBD, LLC, which could significantly expand the company's operations.
• The company received approximately $1.4 million from the issuance of common stock under its ELOC agreement during the quarter.
• Management believes the company is well-positioned to capitalize on the cannabinoid and wellness economy.

Negatives

• Revenue for the three months ended March 31, 2026, was $4,224, a significant decrease from $68,606 in the same period of 2025, primarily due to a lack of operating capital.
• The company has a substantial accumulated deficit of $184.4 million as of March 31, 2026.
• Current liabilities ($16,972,378) significantly exceed current assets ($708,848), resulting in a working capital deficit.
• The company received a notice from NYSE Regulation for non-compliance with continued listing standards due to negative shareholder equity.
• The company is at risk of delisting from the NYSE American if it cannot regain compliance by January 29, 2027.
• The company's stock price has been trading below $0.20 and is at risk of delisting if it falls below $0.10.
• The company has material weaknesses in its internal controls over financial reporting due to a lack of segregation of duties and insufficient accounting personnel.

Risks

• The company may be unable to maintain its listing on the NYSE American due to existing or proposed continued listing requirements, including minimum shareholder equity and stock price thresholds.
• The proposed acquisition of Medterra CBD, LLC is subject to due diligence, execution of a definitive agreement, and raising approximately $10 million in capital, creating significant uncertainty.
• The company's ability to continue as a going concern is dependent on its ability to secure additional funding and successfully execute its business plan, including the Medterra acquisition.
• The company faces significant liquidity challenges and may not have sufficient capital to meet its working capital needs for the next 12 months.
• The company's stock price is volatile and has been trading at low levels, increasing the risk of delisting.
• The company is involved in ongoing discussions and potential settlement of legal matters, including a dispute with Decathlon Alpha IV, L.P. regarding a loan agreement.
• The company has material weaknesses in its internal controls over financial reporting, which could lead to errors in financial reporting.

Future Outlook

The company is transitioning to the regulated wellness and cannabinoid markets and is pursuing a potential business combination with Medterra CBD, LLC. This transaction is subject to due diligence, definitive agreements, and raising approximately $10 million. Management is also exploring alternative transactions in the wellness and cannabinoid sectors. The company's ability to continue as a going concern and maintain its NYSE American listing is contingent on securing additional funding and successfully closing the Medterra acquisition or other strategic transactions.

Management Comments

• Management believes the Company is uniquely positioned to capitalize on the ongoing evolution of the cannabinoid and wellness economy by identifying, partnering with, and supporting established brands across the hemp-derived CBD and, subject to applicable regulatory and exchange approvals, medical cannabis marketplaces.
• Management is pursuing potential alternative transactions over the past 30 days in the wellness and cannabinoid sectors and will provide further updates as they become available.
• The Company expects that the acquisition of Medterra will create sufficient equity and due to Medterra's income the Company does not expect to fail to comply in the future with NYSE listing standards.

Industry Context

StockSavvy.ai notes that Splash Beverage Group's strategic pivot from a struggling beverage business to the high-growth cannabinoid and wellness sector reflects a broader industry trend of companies seeking new avenues for growth and diversification, particularly in markets with significant regulatory evolution and consumer interest.

Comparison to Industry Standards

• The company's revenue of $4,224 for the quarter is significantly below industry benchmarks for established beverage or cannabinoid companies, highlighting its early-stage and transitional phase.
• The substantial operating expenses relative to revenue indicate a high cost structure, which is common in companies undergoing significant strategic shifts or facing capital constraints.
• The pursuit of a merger with Medterra CBD, LLC, valued at $37.6 million, suggests an attempt to acquire a more established player in the cannabinoid market, aligning with industry consolidation trends.
• The company's negative shareholder equity and ongoing liquidity issues are critical concerns when compared to industry standards, where companies typically maintain positive equity and sufficient working capital to fund operations and growth.

Management Changes

Legal Proceedings

• The company is involved in settlement discussions with TapouT LLC regarding a terminated licensing agreement.
• The company is engaged in discussions with Decathlon Alpha IV, L.P. regarding a disputed loan agreement and demand for payment.
• The company is a party to settlement agreements with three prior investors, with extended due dates for settlement payments.
• The company is subject to asserted claims and regulatory actions in the ordinary course of business, though none are anticipated to have a material adverse effect.

Related Party Transactions

• Related party advances from former CEO Robert Nistico totaled approximately $0.4 million outstanding as of March 31, 2026, and December 31, 2025, with interest rates ranging from 4% to 7%.
• Robert Nistico is also a guarantor for certain loans and entered into a consulting agreement with the company.
• The company has a marketing and distribution agreement with SALT Tequila USA, LLC, in which it has a 22.5% ownership interest.

Stakeholder Impact

• Shareholders face significant risk of delisting from the NYSE American, which would reduce liquidity and potentially lead to a loss of investment.
• Creditors and lenders face uncertainty regarding repayment due to the company's liquidity challenges and ongoing disputes, such as with Decathlon Alpha IV, L.P.
• Employees may be impacted by the company's precarious financial situation and potential delisting, affecting job security and future opportunities.
• Potential investors should be aware of the high risks associated with the company's financial instability, ongoing legal matters, and the uncertainty of its strategic pivot.

Next Steps

• Submit a plan to the NYSE by May 29, 2026, detailing actions to regain compliance with continued listing standards by January 29, 2027.
• Continue due diligence and negotiations for the potential acquisition of Medterra CBD, LLC.
• Pursue potential alternative transactions in the wellness and cannabinoid sectors.
• Address the demand letter from Decathlon Alpha IV, L.P. regarding a loan agreement.
• Finalize settlement discussions with TapouT LLC regarding a terminated licensing agreement.

Key Dates

Recommendation

The company exhibits severe financial distress, including a drastic revenue decline, critical liquidity shortages, and a high risk of delisting from the NYSE American. While a strategic pivot to the cannabinoid market is underway with a proposed acquisition, significant capital is required, and the deal's completion is uncertain. The ongoing operational and financial challenges, coupled with material weaknesses in internal controls, present substantial risks to investors.

Keywords

Splash Beverage Group, Form 10-Q, Medterra CBD, Cannabinoid Market, Wellness Products, SEC Filing, Financial Report, Liquidity, NYSE American, Delisting Risk, Business Combination